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Interleukin-23 (IL-23) is required for inflammatory
Th17 cell function in experimental autoimmune
encephalomyelitis (EAE), and IL-23 blockade re-
duces the number of effector Th17 cells in the CNS.
We report that pro-inflammatory Th17 cells express
high integrin b3 that is IL-23 dependent. Integrin b3
was not upregulated on all activated T cells; rather,
integrin b3 was upregulated along with its functional
partner integrin av on effector Th17 cells and ‘‘ex-
Th17’’ cells, and avb3
hi RORgt+ cells expanded dur-
ing EAE. Integrin avb3 inhibitors ameliorated clinical
signs of EAE, and integrin b3 deficiency on CD4
+
T cells alone was sufficient to block EAE induction.
Furthermore, integrin-b3-deficient Th17 cells, but
not Th1 cells, were impaired in their ability to induce
EAE. Integrin b3
/ T cells induced smaller demyeli-
nated lesions and showed reduced spread and
accumulation within the CNS, corresponding with
impaired extracellular-matrix-mediated migration.
Hence, integrin b3 is required for Th17 cell-mediated
autoimmune CNS inflammation.
INTRODUCTION
Th17-mediated inflammation is highly dependent on signals
from interleukin-23 (IL-23), an IL-6 family member cytokine
composed of the common IL-12/IL-23 p40 subunit paired with
the unique p19 subunit (Aggarwal et al., 2003; Cua et al., 2003;
Oppmann et al., 2000; Reboldi et al., 2009). The IL-23 receptor
(IL-23R) is not highly expressed on naive CD4+ T cells, and
accordingly, IL-23 is not required for the early upregulation of
the putative Th17 transcription factor RORgt or for expression
of IL-17 (Zu´n˜iga et al., 2013; Ivanov et al., 2006). Rather, IL-23
is required for Th17 cell proliferation and the switch to effector
phenotype after the initial signals for differentiation have been
provided by transforming growth factor b (TGF-b), IL-6, and
IL-1 (Mangan et al., 2006; Veldhoen et al., 2006; Bettelli et al.,
2006; Chung et al., 2009). The latter two cytokines induce
upregulation of the IL-23 receptor (IL-23R), thus allowing IL-23Cell R
This is an open access article under the CC BY-Nsignals to come into play as Th17 cell differentiation progresses
(Zhou et al., 2007). Hence, it is possible to induce early Th17 cells
in the absence of IL-23 signals in vivo. However, beginning
1 week post-immunization, IL-23R-deficient Th17 cells show
reduced proliferation, lose IL-17 production, and generate few
IL-2IL7RhiCD27lo effector phenotype cells (McGeachy et al.,
2009). IL-23 is also required for granulocyte-monocyte colony
stimulating factor (GM-CSF) production by Th17 cells, which is
critical for EAE induction (Codarri et al., 2011; El-Behi et al.,
2011). Mice deficient in IL-23 or IL-23R are therefore highly
resistant to Th17-mediated autoimmune inflammation, and
monoclonal antibodies targeting IL-23 or IL-17 are proving highly
efficacious in clinical treatment of psoriasis and are currently
being trialed in multiple sclerosis (MS) and other autoimmune
diseases.
In the experimental autoimmune encephalomyelitis (EAE)
model of MS, IL-23R-deficient Th17 cells show defective accu-
mulation in the CNS (McGeachy et al., 2009). Fewer cells in the
blood could partially explain this defect. Alternatively, IL-23R
signaling may confer a migratory advantage on Th17 effector
cells. CCR6 is the key Th17-expressed chemokine receptor
thought to allow initial entry of Th17 cells into the CNS by pro-
moting migration through the choroid plexus (Reboldi et al.,
2009). However, IL-23 is not required for expression of CCR6
(McGeachy et al., 2009).
Integrins are cell-surface receptors that promote migration of
cells into inflamed tissue sites through interactions with inflamed
endothelium and stromal extracellular matrix (ECM) compo-
nents. Integrin blockade is used therapeutically in MS and
Crohn’s disease; natalizumab is amonoclonal antibody targeting
integrin a4-mediated migration of inflammatory T cells into the
brain and gut. While highly effective in some patients, natalizu-
mab therapy carries the risk of progressivemultifocal leukoence-
phalopathy, caused by a rare but frequently fatal uncontrolled
John Cunningham (JC) virus infection in the brain that occurs
due to the inability of virus-specific T cells, including Th1 cells,
to migrate to the CNS after a4 blockade (Hellwig and Gold,
2011; Aly et al., 2011). Furthermore, recent data indicate that in-
tegrin a4 is not absolutely required for Th17 cell entry to the CNS
(Glatigny et al., 2011; Rothhammer et al., 2011). Identification of
integrins that are specifically expressed on Th17 cells, and
particularly in response to IL-23, therefore has great therapeutic
potential.eports 16, 1339–1351, August 2, 2016 ª 2016 The Author(s). 1339
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. IL-23R-Dependent Inflammatory
Th17 Cells Are Integrin b3
hi
CD4+ T cells from CD45.1+ IL-23R/GFP,
IL-23R+/GFP or WT OTII mice were adoptively
transferred into WT B6 recipients that were
immunized the following day with OVA(323–339)
in CFA.
(A) dLN cells were stimulated with PMA/ionomycin
on day 10 and OTII cells analyzed by flow cytometry
for co-expression of IL-17 and integrin b3, gating on
CD4+CD45.1+ cells.
(B) Integrin b3 expression on unstimulated IL-
23R+/GFP+/ CD45.1+ OTII cells taken from dLNs
on day 10.
(C) Integrin b3 expression on IL-23R-deficient (IL-
23R/GFP+/+) CD45.1+ OTII cells taken from dLNs
on day 10.
(D and E) Pooled data for integrin b3 expression on
wild-type and IL-23R/ cells as described above,
gating on unstimulated IL-23R(GFP)+ OTII cells (D)
and IL-17+OTII cells following PMA/ionomycin
stimulation (E).
(F) CD4+ T cells from B6 mice were activated
with plate-bound anti-CD3 under the following
conditions: IL-23, IL-6, IL-1 (Th17(i)), TGF-b +
IL-23, IL-6, IL-1 (Th17(TGF)), IL-12 (Th1), or no
cytokines (Th0), and expression of integrin b3
was assessed by flow cytometry on indicated days
of culture.
(G) Expression of integrin b3 on CD4+ cells cultured
in the presence of IL-23, IL-6, and IL-1 with indicated
concentrations of TGF-b, analyzed by flow cy-
tometry on day 4.
Data are representative of three separate experi-
ments with four mice per group (A–E) or performed in
triplicate (F and G). Statistical significance was as-
sessed by one-way ANOVA. Error bars indicate
mean ± SD.Integrin b3 (Itgb3) is a member of the RGD family of integrins
with two described heterodimeric partners: aIIb is expressed on
platelets, while av is expressed on a wide variety of cells and
pairs with b1, b5, b6, and b8 as well as b3 (Hynes, 2002). Integrin
b3 expression is increased in Th17-associated diseases such as
psoriasis (Goedkoop et al., 2004), psoriatic arthritis (Can˜ete
et al., 2004), rheumatoid arthritis (Kurohori et al., 1995), and
MS (Murugaiyan et al., 2008). However, the functions of integrin
b3 have not been closely studied on immune cells. Integrin avb3
is known to bind ECM proteins, including vitronectin and fibro-
nectin, which show increased expression in the CNS in both
EAE and MS (Han et al., 2008; Teesalu et al., 2001). Integrin
avb3 also binds osteopontin, which is strongly associated with
autoimmune diseases, including MS (Steinman, 2009). Given
these intriguing connections with the IL-23/Th17 axis and integ-
rin avb3, we therefore directly tested the expression and func-
tion of this integrin heterodimer on Th17 cells in the context
of autoimmune disease. We focused our studies largely on
the b3 integrin, since it partners only with av to form a functional1340 Cell Reports 16, 1339–1351, August 2, 2016receptor on T cells, while av can form receptors with multiple a
integrins.
RESULTS
IL-23R-Dependent Th17 Cells Express Integrin b3
To investigate expression of integrin b3 on Th17 cells in vivo, we
used an OTII adoptive transfer system known to drive robust an-
tigen-specific Th17 cell development (McGeachy et al., 2009;
Chen et al., 2011; Chung et al., 2009). OTII cells activated by im-
munization with OVA(323–339) in complete Freund’s adjuvant
(CFA) contained a clear population of IL-17-expressing cells
that had uniformly high expression of integrin b3 (Figure 1A).
Similarly, IL-23R+ cells weremostly integrin b3
hi (Figure 1B), while
themajority of activated but IL-17 or IL-23R cells were integrin
b3
lo. Th17 cells are dependent on expression of IL-23R for devel-
opment of effector functions in vivo (McGeachy et al., 2009). In-
tegrin b3 expression peaked on wild-type (WT) OTII Th17 cells on
day 10 and was strongly dependent on IL-23 signaling, since
IL-23R/ OTII cells showed a significant defect in their ability to
upregulate integrin b3 on Th17 cells (Figures 1C and 1D). IL-17
production is decreased in the absence of IL-23R by day 10
post-immunization, and so we confirmed that the defect in upre-
gulation was consistent in IL-23R/ OTII cells when gating only
on remaining IL-17+ cells (Figure 1E). Integrin b3 expression was
not dependent on IL-12 in vivo, as transfer of WT OTII cells into
IL-12-deficient hosts did not reduce expression on resulting
Th17 cells (data not shown).
TGF-b strongly promotes Th17 development when measured
by expression of RORgt and IL-17, and T cells lacking TGF-b
signaling show a defect in Th17 development and maintenance
in vivo (Zu´n˜iga et al., 2013). However, high levels of TGF-b
signaling result in non-inflammatory Th17 cells that produce IL-
10 and are unable to transfer disease in vivo (McGeachy et al.,
2007; Ghoreschi et al., 2010). In contrast, stimulation of T cells
in the presence of IL-23, IL-6, and IL-1 induces highly inflamma-
tory Th17 cells (Th17(i) cells) (Ghoreschi et al., 2010). In vitro,
Th17(i) showed a time-dependent upregulation of integrin b3
that was significantly greater than Th0 and Th1 cells (Figure 1F).
Furthermore, TGF-b suppressed integrin b3 expression by
Th17(i) cells in a dose-dependent manner (Figures 1F and 1G).
Together, these data support the conclusion that inflammatory
Th17 cells express high integrin b3 that is promoted by IL-23
signaling but suppressed by high levels of TGF-b.
Integrin b3
hi RORgt+ Th17 Cells Increase in EAE
We next investigated integrin b3 expression by Th17 cells during
inflammation in the EAEmodel. Corresponding with the previous
results, IL-17-expressing cells in lymph nodes (LNs) and CNS of
mice with EAE were integrin b3
hi (Figure 2A). Since phorbol 12-
myristate 13-acetate (PMA)/ionomycin stimulation likely over-
estimates the frequency of MOG-specific Th17 cells, we also
confirmed that MOG-specific IL-17 producers are high expres-
sors of integrin b3 in EAE (Figure 2B), and furthermore, integrin
b3 was not altered by PMA/ionomycin stimulation (Figure 2B).
Inboth theOTIImodelandEAE, itwasapparent thata fairly large
proportionof integrinb3
hi cells did not express IL-17 in response to
stimulation. Since conversion of Th17 cells with loss of IL-17 pro-
duction is quite prevalent in EAE, we used IL-17CreYFP fate-
tracking mice and demonstrated that current and prior Th17 line-
age cells accounted for approximately half of integrin b3
hi cells in
draining LNs (dLNs) (Figures 2C and S1A). In contrast, very few
Th17 cells were found in the integrin b3
lo population (Figure 2C).
It is known that the IL17CreYFP cells under-report IL-17 expres-
sion due to the threshold required for Cre expression (Hirota
et al., 2011). In addition, IL-17 production is not the only factor
defining Th17 cells. We therefore analyzed expression of the
putative Th17 cell transcription factor RORgt and found that
most integrin b3
hi cells also expressed RORgt (Figure 2D), and
some of the integrin b3
hi RORgt+ cells co-expressed IL-17 (Fig-
ure 2E). Interestingly, RORgt+ integrin b3
hi cells were almost ab-
sent in naive animals (Figure 2F), and integrin b3
hi T cells were
significantly increased in EAE compared to naive LNs (Figure 2G).
Integrin b3 and Th1 Cells in EAE
Compared to Th17 cells, interferon-g-positive (IFN-g+) cells had
less consistent integrin b3 expression, and only approximatelyhalf of IFN-g+ cells were integrin b3
hi in EAE (Figure 3A). This
was particularly apparent in dLN, where IL-17+ cells had signifi-
cantly higher integrin b3 expression overall than IFN-g
+ cells (Fig-
ure 3B). Fate-tracking studies in EAE previously demonstrated
that a high proportion of IFNg+ T cells are in fact derived from
Th17 precursors, termed ‘‘ex-Th17’’ cells (Hirota et al., 2011).
We therefore employed IL-17CreYFP fate-tracking mice to
further interrogate the relationship between integrin b3 expres-
sion and the Th17 cell lineage in IFN-g-producing cells. YFP
expression marks cells that have produced high amounts of IL-
17 at some time in their differentiation history. In both LN and
CNS, YFP-expressing cells (regardless of IFN-g production)
showed significantly higher integrin b3 expression than YFP

‘‘true Th1’’ cells, which had similar levels to cells that were dou-
ble negative for both IFN-g and YFP (Figure 3C). Hence, integrin
b3 expression is retained on converted ex-Th17 cells, similarly to
IL-1R1 (Hirota et al., 2011).
We observed that some IFN-g-producing cells were also
present in T cells from naive mice (data not shown), suggesting
that PMA/ionomycin stimulation can induce non-specific Th1 re-
sponses. We therefore stimulated EAE dLN and CNS cells with
MOG(35–55). In contrast to PMA/ionomycin induced responses,
EAE T cells that produced IFN-g in response to MOG were
mostly integrin b3
hi (Figure 3D). Furthermore, the majority of
MOG-responsive IFN-g-producing cells were also YFP+, and
the proportion of YFP+ cells was greatly increased in CNS.
Hence, these data support the Th17-driven nature of the EAE
model as previously reported by Hirota et al. (2011), with few
true Th1 cells present, particularly if one analyzes MOG-driven
responses.
Co-expression of Integrins on Th17 and T Regulatory
Cells in EAE versus Naive LN
Integrins are expressed as heterodimers to form functional re-
ceptors, pairing an a and b chain. On leukocytes, integrin b3 is
only known to have one partner: integrin av. As predicted, integ-
rin b3
hi cells were also integrin av
hi, and this avb3
hi population
was largely absent in naive animals (Figure 4A). The staining
pattern of these two integrins gave a consistently linear pattern,
an effect that can occur when autofluorescence or compensa-
tion problems occur. However, the absence of this specific pop-
ulation in naive LN, along with fluorescence-minus-one staining
controls (Figure S2A), instead suggests that integrin b3 and in-
tegrin av are co-expressed, as would be expected for a hetero-
dimeric receptor. To confirm the association between av and
b3 on Th17 cells, we performed co-immunoprecipitation experi-
ments, and as predicted by the literature, b3 was detected upon
av immunoprecipitation, but not the IgG control, and vice versa
(Figures 4B and S2B).
Integrin av also partners with integrin b1, and avb1 was recently
shown to be important for Th1 cell migration in tissues (Over-
street et al., 2013). In EAE, the expanded integrin-av-positive
T cells also expressed integrin b1 (Figure 4C). However, the
pattern of staining was different to av with b3, and approximately
half of integrin b1
hi cells did not express integrin av (Figure 4C).
This suggested that integrin b1
hi cells were not exclusively
Th17 cells, and indeed, this was confirmed by analyzing co-
expression of integrin b1 and RORgt (Figure 4D). Furthermore,Cell Reports 16, 1339–1351, August 2, 2016 1341
Figure 2. Integrin b3 Expression on Th17
Cells in EAE
CD4+ T cells from dLNs and CNS were analyzed
by flow cytometry during active EAE (day 12–16)
induced in IL-17Cre-YFP fate-tracking mice.
(A) Representative flow cytometry plots of integrin
b3 and intracellular IL-17 staining following PMA/
ionomycin stimulation in live CD4+ cells from indi-
cated sites.
(B) IL-17 and integrin b3 co-expression in live CD4+
T cells from naive and EAE LNs, stimulated as
indicated (all EAE plots are from same donor for
comparison).
(C) EAE LN cells were stimulated with PMA/
ionomycin, and live CD4+ cells were then gated
according to high or low integrin b3 expression to
determine expression of intracellular IL-17 protein
and IL17Cre-mediated YFP.
(D) Histogram comparing RORgt expression in in-
tegrin b3hi and integrin b3lo CD4+ EAE LN cells.
(E) EAE LN cells stimulated with PMA/ionomycin
and analyzed for expression of IL-17 and RORgt in
integrin b3hi and integrin b3lo CD4+ cells.
(F) Representative plots of RORgt+integrin b3hi
population within live CD4+ cells from EAE LNs and
naive LNs.
(G) Percentage of integrin b3hi cells gated from live
CD4+ cells, with data pooled from three separate
experiments.
Data are representative of at least three separate
experiments, with two to four mice per group.
Statistical significance was analyzed by one-way
ANOVA. Error bars indicate mean ± SD.while RORgt+ integrin b1
hi cells expanded in EAE compared to
naive LN, a population of integrin b1
hi cells was consistently pre-
sent in naive animals (Figure 4D). Unlike integrin b3, there are
multiple potential partners for b1 heterodimers. Integrin a4 was
expressed on few Th17 cells (Figure 4E), in accordance with pre-
vious findings that Th17 cells are less dependent on integrin a4
than Th1 cells (Glatigny et al., 2011; Rothhammer et al., 2011).
Integrin a6 was only present on a few T cells in EAE and not on1342 Cell Reports 16, 1339–1351, August 2, 2016Th17 cells (Figure S3A). Integrin a2 has
been reported to be expressed with b1 on
Th17 cells (Gagliani et al., 2015; El Azreq
et al., 2013). In EAE, less than half of Th17
cells expressed integrin a2 (Figure 4F).
Integrin a2b1 has also been reported on
T regulatory cells (Gagliani et al., 2015).
Indeed, integrin b1 was expressed on
approximately half of Foxp3+ regulatory
T cells in LN from both naive and EAE
mice (Figure 4G), although a smaller pro-
portion of regulatory cells also expressed
integrin a2 (Figure 4H). In contrast, most
Foxp3+ T regulatory cells were integrin
b3
lo (Figure 4I). As expected for expanded
helper T cells, integrin b3
hi T cells were
exclusively found in the CD44hi-activated
cell population during EAE and were espe-cially enriched in CD44hiCD27lo effector T cells (Figure 4J). How-
ever, it is important to note that integrin b3
hi T cells constituted
<20% of the CD44hiCD27hi-activated T cell population and
only half of the CD44hiCD27lo effector T cell population (Fig-
ure 4J). As suggested by our finding that integrin b1
hi cells
were present in naive animals and expressed by other T helper
populations including regulatory T cells, integrin b1 was ex-
pressed on 75% of both activated and effector T populations
Figure 3. Integrin b3 and Th1 Cells in EAE
CD4+ T cells from dLNs and CNS were analyzed
by flow cytometry during active EAE (day 12–16)
induced in IL-17Cre-YFP fate-tracking mice.
(A) Representative flow cytometry plots of integrin
b3 and intracellular IFN-g staining following PMA/
ionomycin stimulation in live CD4+ cells from indi-
cated sites.
(B) Geometric mean fluorescence intensity (MFI) of
integrin b3 expression on cells positive by intracel-
lular cytokine staining for IFN-g and IL-17 at indi-
cated sites.
(C) Geometric MFI of integrin b3 expression on LNs
and CNS CD4+ T cells gated according to co-
expression of IFN-g and YFP as indicated.
(D) IFN-g and integrin b3 co-expression by live CD4+
T cells from EAE LNs and CNS, stimulated with
MOG(35–55) overnight, or with no stimulation in
media-only control.
Data are representative of at least three experiments
with three to five mice per group. Statistical signifi-
cance was analyzed by one-way ANOVA. Error bars
indicate mean ± SD. See also Figure S3.(Figure 4K). The levels of integrin b1 were high on both IL-17
+ and
IFN-g+ T cell populations in the LN and CNS, and did not vary be-
tween ex-Th17 IL-17Cre-YFP+ and YFP cells (Figures S3B and
S3C). Although not an extensive analysis of integrin expression
by helper T cell subsets, taken together, these data point to in-
tegrin b3 forming a heterodimer with av specifically on Th17 cells
that expand in response to EAE induction. Th17 cells also ex-
press other integrins, particularly integrin b1, and some Th17
cells expressed a2 or a4. However, none of these integrinsCell Rshowed Th17-constrained expression to
the degree of integrin avb3. Therefore, we
focused our functional analyses on the re-
quirements for integrin avb3 by specifically
blocking b3 in Th17 cells.
Integrin avb3 Is Functionally
Important for Th17-Mediated CNS
Inflammation
To test the requirement for integrin b3 in
Th17-mediated EAE, MOG-reactive cells
were expanded from immunized Itgb3/
or from control Itgb3+/ donor LN in the
presence of IL-23 before transfer to naive
recipients. As expected, integrin b3 defi-
ciency significantly reduced the ability of
IL-23-driven cells to transfer EAE (Fig-
ure 5A). In contrast, Itgb3/ Th1 cells
expanded in presence of IL-12 were
capable of transferring EAE (Figure 5B).
The incidence of EAE inWTTh17 cell recip-
ients was 12/15 (80%) compared to 5/15
(30%) in recipients of Itgb3/ Th17 cells,
and correspondingly few CNS lesions and
infiltrating CD4+ cells were found in these
resistant mice (Figure 5C).We wanted to confirm that defects in ability of Itgb3/ Th17
cells to transfer EAE were not due to developmental effects or
priming in the knockout donors. We therefore transferred WT
Th17 cells and administered cilengitide, a modified compound
of cRGDfv, developed to have increased sensitivity for integrin
avb3 (Mas-Moruno et al., 2010; Reardon et al., 2008). Integrin
avb3 inhibition also significantly reduced severity of Th17-medi-
ated EAE (Figure 5D), and these data support the role of integrin
avb3 in the effector phase rather than early activation of Th17eports 16, 1339–1351, August 2, 2016 1343
Figure 4. Integrin b3 Expression by Activated and Effector T Cells
Live CD4+ T cells from dLNs were analyzed by flow cytometry during active EAE (day 12–16) and from naive controls as indicated.
(A) Co-expression of integrin b3 and integrin av.
(B) Co-immunoprecipitation of av and b3 from in vitro-differentiated Th17 cells as described in Figure 1F. Lysates were immunoprecipitated with anti-av or IgG
control, and immunoblot was performed for b3 and av as indicated.
(legend continued on next page)
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cells. We also confirmed that avb3 inhibition by cilengitide admin-
istration from day 4 after active immunization with MOG(35–55)
resulted in significantly reduced EAE severity compared to con-
trol mice (Figure 5E). Together, these data support a critical
targetable role for integrin avb3 expression by Th17 cells for their
pro-inflammatory functions in autoimmune disease.
To further confirm the requirement for integrin avb3 in Th17
inflammatory cell function, we generated Itgb3/ 2D2 mice, in
which CD4+ T cells bear a transgenic T cell receptor (TCR) reac-
tive to MOG(35–55). Th17 cells were differentiated from these
mice in vitro, resulting in equivalent expression of IL-17 (Fig-
ure 6A). Following resimulation according to the protocol estab-
lished by Ja¨ger et al. (2009), equal numbers of effector Th17 cells
were transferred to naive recipients. Itgb3/ 2D2 Th17 cells
were again found to be significantly impaired in their capacity
to induce EAE (Figure 6B). Spinal cords from recipients of WT
2D2 Th17 cells showed large demyelinated lesions, with exten-
sive infiltration of CD4+ T cells consistently apparent even
beyond the main inflammatory cellular focus (Figures 6C and
6D). In contrast, spinal cords from recipients of Itgb3/ 2D2
Th17 cells had smaller demyelinated lesions and fewer inflam-
matory infiltrates, and the CD4+ T cells appeared to bemore con-
tained within the inflammatory cell infiltrate, in contrast to the
rather diffuse distribution of WT 2D2 cells (Figures 6C and 6D).
Integrinb3-Deficient Th17Cells AreExpandedbut Fail to
Accumulate in the CNS during EAE
To determine the T cell-specific impact of integrin b3 deficiency
during active EAE induction, we isolated CD4+ T cells from
Itgb3/ mice and transferred them into RAG1/ mice, which
lack T and B cells but have normal expression of integrin b3 in
vasculature and innate immune cells. Recipients of Itgb3/
T cells were resistant to EAE induction by immunization with
MOG(35–55), with only 20% of mice showing mild clinical signs,
compared to 100% incidence and greater severity in controls
that received CD4+ T cells isolated from Itgb3+/ littermates (Fig-
ure 7A). There was no difference in the number of IL-17-produc-
ing cells in dLNs prior to onset of EAE (Figure 7B), indicating that
activation and expansion of Th17 cells does not require integrin
b3 in vivo. Likewise, the number of IFN-g-producing cells was not
affected by integrin b3 deficiency (Figure 7C).
To further confirm that integrin b3 is not required for Th17 dif-
ferentiation in vivo, we transferredWT or Itgb3/ 2D2 T cells into
WT recipients and immunized with MOG in CFA. In this model,
we could specifically analyze MOG-specific T cell expansion
and differentiation. As reported previously for 2D2 adoptive(C) Co-expression of integrin b1 and integrin av in EAE.
(D) Co-expression of RORgt and integrin b1.
(E) Co-expression of IL-17 and integrin a4.
(F) Co-expression of IL-17 and integrin a2.
(G) Co-expression of integrin b1 and Foxp3.
(H) Co-expression of integrin a2 and Foxp3.
(I) Co-expression of integrin b3 and Foxp3.
(J) Proportion of effector (CD44hiCD27lo), activated/memory (CD44hiCD27hi), and
(K) Proportion of effector (CD44hiCD27lo), activated/memory (CD44hiCD27hi), and
Data are representative of at least three independent experiments with two to four
Statistical significance was analyzed by one-way ANOVA. Error bars indicate metransfers, we were unable to track 2D2 cells in vivo after
day 10 post-immunization (Reboldi et al., 2009). However, the
number of IL-17-producing 2D2 T cells generated in dLNs was
not affected by integrin b3 deficiency (Figure 7D), supporting
our conclusion that integrin b3 is not required for Th17 cell
differentiation.
We then examined the CNS infiltration of Itgb3/ T cells dur-
ing the clinically active phase of EAE. Similarly to the passive
transfer results, few Itgb3/ CD4+ T cells were found in the
CNS (Figure 7E), corresponding with the failure to induce EAE.
Likewise, the absolute number of cytokine producing cells,
particularly IL-17+ cells, in the CNS was greatly reduced in
Itgb3/ recipients (Figures 7F and 7G). These data are consis-
tent with a model in which integrin b3 is not required for early
Th17 differentiation, but is required for effector Th17 cells to
initiate and sustain inflammation. A similar observation was
made for integrin b1 in Th1-mediated dermal inflammation (Over-
street et al., 2013), in which ECM-mediatedmigration of Th1 cells
within interstitial tissue resulted in impaired effector function. We
therefore tested the capacity of integrin b3 to mediate migration
of Th17 cells to ECM using a transwell migration assay. Inflam-
matory Th17 cells (Itgb3hi) showed strong fibronectin-induced
migration, which was blocked by the avb3 inhibitor cilengitide
(Figure 7H). As a negative control, we tested migration of Th17
cells generated in the presence of TGF-b (Itgb3lo but Itgb1hi).
These Th17 (TGF) cells (with low integrin b3 expression) also
showed fibronectin-induced migration. However, Th17(TGF)
cell migration was significantly reduced compared to Th17(i)
cells, and was also not inhibited by cilengitide. This suggests
that integrin b3 plays a dominant role in inflammatory Th17
migration that is only partially redundant with other migratory
mechanisms such as integrin b1. Finally, we confirmed that
Itgb3/ T cells cultured under Th17(i) conditions have impaired
fibronectin-induced migratory capacity (Figure 7I). Hence, integ-
rin avb3 plays a role in ECM-directed migration that correlates
with impaired accumulation of integrin-b3-deficient cells in the
CNS after EAE induction by active immunization or passive
transfer.
DISCUSSION
IL-23 is known to be important for Th17 effector functions, but
not for early differentiation. Our data describe a role for integrin
b3 expression by IL-23R-dependent inflammatory Th17 cells. In-
tegrin b3 was almost exclusively expressed on RORgt
+ Th17
cells during EAE, expression directly correlated with expressionnaive (CD44loCD27hi) CD4+ cells that were integrin b3hi in EAE LNs.
naive (CD44loCD27hi) CD4+ cells that were integrin b1hi.
mice per group; data in (I) and (J) were pooled from two separate experiments.
an ± SD.
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Figure 5. Integrin b3 Is Important for Th17-
Mediated EAE Induction
(A) EAE was passively induced by stimulating T cells
from MOG(35–55)-immunized Itgb3/ and Itgb3+/+
donors with MOG(35–55) in presence of IL-23 to
expand Th17 cells before transfer into wild-type
recipients.
(B) Passive EAE induction by T cells taken from
immunized Itgb3/ and Itgb3+/+ donors and stim-
ulated with MOG(35–55) in presence of IL-12 to
expand Th1 cells before transfer into wild-type
recipients.
(C) Representative immunofluorescence staining
of spinal cord sections from recipients of MOG-
stimulated WT or Itgb3/ Th17 cells, analyzed at
peak of disease, showing CD4+ T cells, nuclear stain
(DRAQ5), and myelin (scale bars indicate 200 mm).
(D) C57B/6 mice received passive transfer of WT
MOG(35–55)-stimulated Th17 cells, with cRGD
(cilengitide) inhibitor treatment administered daily
from day of transfer.
(E) C57Bl/6 mice were immunized to induce EAE
and treated daily from day 4 with 100 mg cRGDfv to
inhibit integrin b3 or PBS control. Clinical signs were
monitored.
Data are pooled from four (A), two (B and D), and
three (E) experiments with four to six mice per group,
and statistical significance of EAE scores was as-
sessed by a Mann-Whitney test separately for each
time point.of integrin av, and co-immunoprecipitation experiments
confirmed that Th17 cells express avb3. In LNs from naive ani-
mals, very few integrin b3
hi cells were present, corresponding
with the paucity of Th17 cells in peripheral LNs in absence of
inflammation. Th17 cells also expressed integrin b1, although
this integrin appears to be much more broadly expressed, and
was found to be present in naive animals and on regulatory
T cells. Th17 cells have been reported to express a2b1, as have
regulatory T cells (Gagliani et al., 2015; El Azreq et al., 2013).
Integrin a4b1 is also expressed by inflammatory T cells and is tar-
geted by natalizumab in MS. However, we found that a4 expres-
sion was low on Th17 cells, fitting with reports that Th17 cells are
less dependent on a4b1 compared to Th1 cells (Rothhammer
et al., 2011; Glatigny et al., 2011). It is possible that integrin
a2b1 or a4b1 (or indeed other integrins) expression partially com-
pensates in Itgb3/ Th17 cells, to allow partial EAE induction.
We have not observed any increase in integrin b1 expression1346 Cell Reports 16, 1339–1351, August 2, 2016on Itgb3/ T cells, while av expression
is typically reduced (A.L.-H., unpublished
data). Since chemokine receptors, such
as CCR6, also mediate entry into the
CNS, it is likely that the small lesions estab-
lished by Itgb3/ Th17 cells reflect this
redundancy in migratory mechanisms and
in fact highlight the strength of Th17 cell
dependence on this particular integrin for
EAE induction.
High integrin b3 expression was main-
tained on IFN-g-producing ex-Th17 cellsidentified through fate-tracking studies. In contrast to the
commonly proposed role of IL-23 in stabilizing the Th17 pheno-
type, three independent labs have shown that IL-23 signaling is
in fact required for conversion of Th17 cells to Th1 (Duhen et al.,
2013; Haines et al., 2013; Hirota et al., 2011). IL-23-mediated
conversion corresponds with a predominance of Th1/Th17 dou-
ble producers typically found in sites of IL-23-associated tissue
inflammation. Hirota et al. similarly demonstrated that IL1R1 was
maintained on ex-Th17 cells in EAE (Hirota et al., 2011). There-
fore, the high expression of integrin b3 on converted ex-Th17
cells supports the role of IL-23 signaling in this process. The
finding that integrin b3
hi cells are enriched in CD44hiCD27lo
effector populations also corresponds with previous data
showing that IL-23 is required for the transition of activated
Th17 cells to CD44hiCD27lo effector Th17 cells (McGeachy
et al., 2009). It was also interesting to note that MOG-induced
IFN-g production particularly strongly associated with ex-Th17
Figure 6. Role of Integrin b3 in 2D2 Th17 Cell
Transfer
(A) Itgb3/2D2 and Itgb3+/+2D2 donor cells were
activated under Th17-inducing conditions and IL-17
production confirmed by flow cytometry.
(B) Passive EAE induction by Itgb3/ 2D2 and
Itgb3+/+ 2D2 donor cells Th17 differentiated in vitro.
Day of onset varied between experiments, so day
0 was designated as first day clinical signs were
observed in the control group in order to determine
statistical significance of pooled experiments.
(C) Representative immunofluorescence staining of
spinal cord sections from recipients of MOG-stim-
ulated WT or Itgb3/ 2D2 Th17 cells, analyzed at
peak of disease, showing CD4+ T cells, nuclear stain
(DRAQ5), and myelin (scale bars indicate 200 mm).
(D) Representative immunofluorescence staining of
spinal cord sections from recipients of MOG-stim-
ulated WT or Itgb3/ 2D2 Th17 cells, showing CD4
distribution across upper right quadrant of spinal
cord cross-section.
Data are pooled from four experiments with four to
five mice per group. Statistical significance of EAE
scores was assessed by Mann-Whitney separately
for each time point.cells, and with high integrin b3 expression, in comparison to
PMA/ionomycin stimulation, further supporting that active
induction of EAE by immunization with MOG(35–55) induces
a predominantly Th17 response. It would therefore be inter-
esting to compare expression of integrins in a strongly Th1-
dependent context, such as infection with known Th1-depen-
dent pathogens.
Integrin avb3 hasmany ligands. Several are ECMproteins such
as fibronectin and vitronectin, and these are strongly upregu-
lated in the CNS during EAE as well as in brain samples from pa-
tients with MS (Teesalu et al., 2001; Han et al., 2008). Many of
these ECM proteins have been proposed to contribute to CNS
inflammation in their capacity as coagulation and pro-angiogenic
factors (Steinman, 2008). Our data suggest an additional func-
tion in promoting migration of inflammatory T cells into the
CNS parenchyma to establish inflammatory foci. Early migrationCell Rinto the CNS is thought to bring T cells to
the subarachnoid space via the blood-
cerebrospinal barrier (Sallusto et al., 2012;
Goverman, 2009; Ransohoff et al., 2003)
and can be mediated by chemokine recep-
tors, particularly CCR6 (Reboldi et al.,
2009). A second stage of T cell activation
and migration within the CNS is then
required to establish the inflammatory sig-
nals that lead to demyelination (Goverman,
2009), leading to fulminant neurological
damage. This stage is not well defined,
and our data support a role for integrin
avb3 in this process. Similar defects in inter-
stitial migration have been reported for Th1
cells in an integrin-avb1-dependent manner
(Overstreet et al., 2013).Integrin avb3 signaling has been reported tomediate additional
functions apart from migration. In a Th2 transfer model, integrin
avb3 was found to promote contact-dependent activation of mi-
croglia by myelin-reactive T cells (Roy et al., 2007). That study
focused on the protective effect of Th2-induced neurotrophins
in vitro. However, it is feasible that reduced microglia activation
by Itgb3/ Th17 cells arriving in the CNS could also contribute
to their inability to establish inflammation and recruitment of
further inflammatory immune cells. Integrin avb3 signaling may
also promote CD8+ T cell cytotoxic functions (Lacy-Hulbert
et al., 2007; Doucey et al., 2003; Ma et al., 1997). Osteopontin,
an integrin avb3 ligand, has been shown to enhance CD4
+
IL-17 production in an integrin-b3-dependent manner in EAE
(Murugaiyan et al., 2008) and in concanavalin A (con-A)-induced
hepatitis (Diao et al., 2012), although we could not find a role for
osteopontin in IL-17 production in our systems (data not shown).eports 16, 1339–1351, August 2, 2016 1347
Figure 7. Integrin b3 Is Required for Accumulation of Th17 Cells in CNS
Itgb3/ and Itgb3+/ CD4+ T cells were transferred into separate RAG/ recipients that were immunized for EAE.
(A) Mean EAE clinical scores monitored.
(B) Absolute number of IL-17+ T cells in LNs on day 12 post-immunization.
(C) Absolute number of IFN-g+ T cells in LNs day 12.
(D) CD4+ T cells from naive wt or Itgb3/ 2D2 mice were transferred into naive CD45.1 recipients that were immunized for EAE. Numbers of IL-17+ 2D2 cells in
dLNs were analyzed on days 6 and 10 post-immunization.
(E) Mice were transferred and immunized as in A, and absolute number of CD4+ cells in CNS analyzed on day 22.
(F) Absolute number of IL-17+ T cells in CNS on day 22.
(G) Absolute number of IFN-g+ T cells in CNS on day 22.
(H) Transwell migration assay of Th17 cells cultured under Th17(i) integrin b3-promoting conditions or under Th17(TGF) integrin b3-suppressing conditions, in
presence or absence of cRGD inhibitor, wells were coated with fibronectin or PBS as indicated.
(I) Transwell migration assay of WT and Itgb3/ T cells cultured under Th17(i) conditions.
Data shown are pooled from three experiments with three to fivemice per group, except (D), whichwas repeated twice, and (H) and (I), which are representative of
three separate experiments. Statistical significance was assessed by Student’s t test, except for (H), whichwas assessedwas by one-way ANOVA, and (A), which
was assessed by Mann-Whitney test separately for each time point of EAE. Error bars indicate mean ± SD.Osteopontin and vitronectin interactions with integrin avb3 are
important in endothelial cell survival as well as migration during
angiogenesis (Scatena et al., 1998; Courter et al., 2005). Osteo-
pontin also promotes survival of encephalitogenic T cells in EAE
(Hur et al., 2007), although specific receptors have not been
identified. While we cannot formally rule out a contribution of
direct osteopontin signaling through integrin avb3 on Th17 cells,
in our study, we did not find consistent evidence for poor survival
or reduced IL-17 production in Itgb3/ T cells. Osteopontin
binds several receptors that are present in the absence of integ-
rin avb3, which could account for some of the differences be-
tween Itgb3/ and osteopontin-deficient mice. However, it
does remain feasible that the pro-inflammatory functions of in-
tegrin avb3 extend beyond tissue migration.
The finding that cilengitide, a compound already being evalu-
ated in humans for cancer therapy, was able to reduce EAE1348 Cell Reports 16, 1339–1351, August 2, 2016severity supports further investigation into the potential of target-
ing integrin avb3 therapeutically. Blockade of av using a similar
inhibitor, cRGDfV, has previously been shown to block EAE
development when administered from time of immunization
(Acharya et al., 2010), an effect that was attributed to the role
of integrin av role in activating TGF-b on dendritic cells during
initial Th17 cell activation. We therefore initiated cilengitide treat-
ment on day 4 after immunization, at which time the initial pre-
sentation of antigen with TGF-b signaling is expected to have
occurred. The efficacy of cilengitide for ameliorating EAE
induced by previously activated Th17 cells further supports the
use of this therapy to block relapses in diseases such as MS.
In summary, we report that integrin avb3 is highly expressed on
effector Th17 cells in an IL-23-dependent manner. Although in-
tegrin-avb3-expressing cells showed an activated phenotype, in-
tegrin avb3 expression was not a marker of all activated T cells or
Th1 cells, but it enriched for cells of the Th17 lineage that
expanded during EAE. This was in contrast to integrin b1 which
showed broader expression on activated T cells. Furthermore,
Th17 cells required integrin b3 expression for efficient induction
of EAE by either passive transfer of activated cells or active im-
munization with MOG(35–55). This role for integrin avb3 expres-
sion corresponds with previous reports suggesting a role for
IL-23 in promoting LN egress and migration into the CNS
(McGeachy et al., 2009). Hence, this study identifies integrin
avb3 as an IL-23-dependent Th17-expressed molecule with
important functions that could be targeted by therapeutic
intervention.
EXPERIMENTAL PROCEDURES
Mice
C57Bl/6, CD45.1+, OTII, IL-17Cre, ROSAfl/flYFP, and RAG1/ and Itgb3
(integrinb3) knockout mice were purchased from Jackson Laboratory. IL-23
RGFP reporter mice were a kind gift from Dr. Vijay Kuchroo (Brigham and
Woman’s Hospital, Harvard Medical School).
Study Approval
Animals were housed under specific-pathogen-free conditions in an Associa-
tion for Assessment and Accreditation of Laboratory Animal Care International
(AAALAC)-approved facility and all animal procedures were approved by the
Institutional Animal Care and Use Committee at the University of Pittsburgh.
OTII Adoptive Cell Transfers
Recipient mice (B6, CD45.2+) received 105 CD45.1+ Il23ra/ or Il23ra+/ OTII
CD4+ T cells intravenously 1 day before immunization with 100 mg OVA(323–
339) (Bio synthesis) in 10 mg/ml CFA (Difco Laboratories) subcutaneously in
the flank. On day 6/7 and day 10 post-immunization, mice were sacrificed
and dLNs were harvested; cells were stimulated with PMA and ionomycin
for 4 hr in the presence of golgiplug before flow cytometry analysis.
In Vitro CD4+ T Cell Differentiation
CD4+ T cells from spleens and lymph nodes of naive mice were purified by
magnetic separation (Miltenyi Biotec). T cells were activated by plate-bound
anti-CD3 (clone 145-TC11, 5 mg ml1; BioXcell) in IMDM medium supple-
mented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin, and 50 mM2-b-mercaptoethanol, HEPES, and Na py-
ruvate for 3–4 days in the presence of recombinant mouse IL-1b, IL-23 (each
20 ng/ ml), and IL-6 (50 ng/ml) for Th17(i), with IL-6 plus TGF-b1 (5 ng ml1)
for Th17(TGF); all cytokines were obtained from R&D Systems. In all Th17
cell cultures, anti-IFN-g neutralizing antibodies (5 mg ml1, BioXcell) were
added. For Th1 cultures, IL-12 (PeproTech) was added at 20 ng/ml.
2D2 Adoptive Cell Transfers
Recipient mice (B6, CD45.1+) received 105 CD45.1 Itgb3/ or Itgb3+/ 2D2
CD4+ T cells 1 day before immunization according to EAE immunization proto-
col. On day 6 and day 10 post-immunization, mice were sacrificed and dLNs
were harvested; cells were stimulated with PMA and ionomycin for 4 hr in
the presence of golgiplug before flow cytometry analysis.
EAE Induction
Active immunization: mice were immunized subcutaneously with 100 mg
MOG(35–55) (Bio synthesis) emulsified in 200 ml CFA (Difco Laboratories) con-
taining 100 mg heat-killed Mycobacterium tuberculosis H37Ra (Difco Labora-
tories) distributed in four sites on the flank. 200 ng pertussis toxin (List Biolog-
ical Laboratories) was given intraperitoneally on days 0 and 2. For RAG/
transfer experiments, dLNs and spleen were harvested from donor C57Bl/6
mice, Itgb3/ mice, or Itgb3+/ littermates, and CD4+ cells were isolated by
magnetic separation using CD4 microbeads (Miltenyi Biotec). 3–10 million
CD4+ cells were transferred intraperitoneally to naive RAG1/ recipients,
which were immunized the following day as described above.For passive transfer of EAE, donor Itgb3/mice or Itgb3+/ littermates were
immunized with MOG(35–55) in CFA. On day 8, LNs and spleen were har-
vested and cells were cultured with 20 mg/ml MOG(35–55) in the presence of
20 ng/ml IL-23 (Th17) or IL-12 plus IL-2 (Th1). 3 days later, cell cultures were
harvested and 2.5 3 107 cells were transferred into naive B6 recipients, with
injection of pertussis toxin on day 0 and day 2. Alternatively, LNs and spleen
were harvested from WT or Itgb3/ 2D2 mice and stimulated in vitro accord-
ing to protocol described by Ja¨ger et al. (2009).
For the RGD blockade of integrin b3, 100 mg cRGD peptide (Peptide Insti-
tute) in PBS (HyClone) was injected subcutaneously daily from day 4 until
day 8 and then from day 15 to day 21, twice daily from day 9 to day 14. The
control group received equal volume of PBS.
EAE was assessed according to the following clinical grades: 1, flaccid tail;
2, impaired righting reflex and hindlimbweakness; 3, partial hindlimb paralysis;
4, complete hindlimb paralysis; 5, hindlimb paralysis with partial forelimb
paralysis; and 6, moribund/dead.
Flow Cytometry
The following fluorescent-activated cell sorting (FACS) antibodies were pur-
chased from BD Biosciences: CD4 (RM4-5), CD44 (IM7), CD27 (LG.3A10),
integrin av (RMV-7), IFN-g (XMG1.2), and IL-17 (TC11-18H10). The following
were purchased from eBioscience: integrin b1 (eBioHMb1-1), integrin b3
(2C9.G3), integrin a2 (DX5), integrin a4 (R1-2), integrin a6 (GoH3), RORgt
(AKFJS9), Foxp3 (FJK-16 s). For cytokine analysis, cells were cultured in
completemedium (RPMImedia containing 10% fetal calf serum (FCS), supple-
mented with Pen-Strep, L-glutamine, HEPES, sodium pyruvate, and 2-ME)
with 50 ng/ml PMA and 500 ng/ml ionomycin (both Sigma-Aldrich) in the pres-
ence of Golgiplug (BD Biosciences) for 3 to 4 hr followed by FACS staining and
analysis. For intracellular cytokines, staining was performed using Cytofix-
cytoperm kit from BD; RORgt and Foxp3 intracellular stains were performed
using an eBioscience Foxp3 staining kit according to the manufacturer’s
instructions.
Immunoprecipitations and Western Blotting
Western blotting and immunoprecipitations were performed as described pre-
viously (Garg et al., 2015, McCarty et al., 2005). Anti-aV (EMD Millipore) and
anti-b3 (Santa Cruz Biotechnology) antibodies were used for immunoprecipita-
tion and anti-aV and anti-b3 (Cell Signaling Technology) antibodies were used
for western blotting. Blots were developed using a FluorChem E imager (Pro-
tein Simple).
Immunofluorescence Staining
Micewere sacrificed and perfusedwith PBS followed by 2%PFA. Spinal cords
were removed and post-fixed in 2% PFA followed by immersion in 30%
sucrose overnight; tissue was then embedded and frozen in Optimal Cutting
Temperature (OCT; Tissue-Tek). 6-mm sections were stained with CD4-
BV421 (BD Biosciences), FluoroMyelin Green (Invitrogen), and nuclear stain
DRAQ5 (BD Biosciences). Slides were mounted with Gelvatol mounting media
and images acquired on Evos FL Auto microscope.
Migration Assays
CD4+ T cells were isolated from spleen of C57Bl/6 or Itgb3/mice by negative
selection and magnetic sorting (Miltenyi Biotech). To generate Th17 cells,
T cells were cultured in RPMI 1640 medium supplemented with 10% FCS,
IL-6, IL-23, IL-1b, and anti-IFN-g antibody, with or without TGF-b1, in plates
coated with anti-CD3 antibody. Cells were harvested between days 5–7 of cul-
ture and resuspended in migration medium (RPMI with 2% BSA). Migration
was assayed in 96-well cell-permeable chambers (5-mmpore size polycarbon-
ate membranes) which had been pre-coated by incubation with rat fibronectin
(Sigma; 10 mg/ml), vitronectin (Sigma; 1 mg/ml) or nomatrix at 37C for 2 hr, and
remaining protein binding sites blocked with RPMI/BSA for 1 hr. 43 104 T cells
were added to the upper chambers, and RPMI containing 1% FCS was added
to the lower chambers. In some cases, GRGDNP peptide (Enzo Life Sciences)
was added to upper chambers at 2 mg/ml. After 2 hr, the upper chambers were
removed, and migrated cells in the lower chamber were stained with Calcein
AM (1 mM; Invitrogen) and visualized and counted by imaging plate reader
(Cytation 3; BioTek).Cell Reports 16, 1339–1351, August 2, 2016 1349
Statistics
One-way ANOVA (for multiple groups) or Student’s t tests were performed for
experiments with parametric values (such as FACS %); Mann-Whitney U test
was performed for EAE experiments, analyzing scores for each day separately.
p values are shown as *p < 0.05, **p < 0.01, and ***p < 0.001, where statistical
significance was found, and all data are presented as means + SD.
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